×ÉѯÈÈÏß
18616108315
18616108315
²úÎï·ÖÀà
Product CategoryÏêϸ½éÉÜ
| Æ·ÅÆ | ³¢¾±´Ú±ð-¾±³¢²¹²ú/Àî¼ÇÉúÎï |
|---|
°ä°Õ26.°Â°Õ£¨Ð¡Êó½á³¦°©Ï¸°û£©ÃèÊö
GES-1£¨ÖÐÎÄÃû³Æ£ºÐ¡Êó½á³¦°©Ï¸°û£©£¬À´Ô´ÓÚСÊó½á³¦°©Ï¸°û£¬Õý³£µÄϸ°ûÐÎ̬Ϊ³ÉÏËάϸ°û£¬Ìù±ÚÉú³¤¡£
¶©¹ºÐÅÏ¢
²úÎïÃû³Æ | »õºÅ | ¹æ¸ñ |
CT26.WT | AX31L403 | T25/1 mL |
ÔËÊ䷽ʽ
³£ÎÂ/¸É±ùÔËÊä¡£
°ä°Õ26.°Â°Õ£¨Ð¡Êó½á³¦°©Ï¸°û£©Ê¹Ó÷½·¨
ÅàÑø·½·¨
ÅàÑø»ù | RPMI-1640£¨GIBCO: C11875500BT£©90%, Fetal Bovine Serum(GIBCO:10099-141)»òºÍÔªÀî¼ÇÌؼ¶Ì¥Å£ÑªÇå (Foetal Bovine Serum)£¨»õºÅ£ºAC03L055£© 10% |
ÅàÑøÌõ¼þ | 37¡æ 5% CO2 |
Ïû»¯Ìõ¼þ | 0.25% Trypsin- EDTA(GIBCO: 25200-056)£¬Ïû»¯1-2min |
´«´ú±ÈÀý | 1:3-1:6 |
»»ÒºÊ±¼ä | 2-3Ìì»»ÒºÒ»´Î |
¶³´æ·½·¨
¶³´æÒº | 55%ÅàÑø»ù£¬40%FBS, 5% (v/v) DMSO »ò ºÍÔªÀî¼Ç¿ìËÙϸ°û¶³´æÒº£¨ÎÞѪÇå¡¢ÎÞµ°°×£©£¨»õºÅ£ºAC05L033£© |
¶³´æÃÜ¶È | 1-3 ¡Á106 /¹Ü£¬Òºµª±£´æ |
¡¡ ¾ßÌå²Ù×÷·½·¨¼ûϸ°ûʹÓÃ˵Ã÷Êé
×¢ÒâÊÂÏî
±¾²úÎï½öÏÞÓÚ¿ÆѧʵÑéÑо¿Ê¹Ó㬲»µÃÓÃÓÚÁÙ´²Õï¶Ï¡¢ÖÎÁƵÈÁìÓò¡£
µ±ÊÕµ½Ï¸°ûºó£¬Çë×ÐϸÔĶÁϸ°ûʹÓÃ˵Ã÷Ê飬°´¹æ¶¨²Ù×÷²¢¼Ç¼ϸ°û״̬£¨ÅÄÕÕ£©¡£ÎÒ˾Ϊ¿Í»§ÌṩһÖÜÄÚµÄÊÛºó±£ÕÏ£¬Ìض¨Çé¿öÏ¿ÉÃâ·ÑÖØ·¢Ï¸°û¡£
²Î¿¼ÎÄÏ×
Wang M, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154: 4685-4692, 1995. PubMed: 7722321
Ïà¹Ø²úÎïÍƼö
Ìؼ¶Ì¥Å£ÑªÇå (Foetal Bovine Serum)£¨»õºÅ£ºAC03L055£©
RPMI-1640 medium (º¬L-¹È°±µÄõ£°·)£¨»õºÅ£ºAC01L064£©
±¾²úÎï½öÏÞÓÚ¿ÆѧʵÑéÑо¿Ê¹Ó㬲»µÃÓÃÓÚÁÙ´²Õï¶Ï¡¢ÖÎÁƵÈÁìÓò¡£
²úÎï×Éѯ
΢ÐÅ×Éѯµç»°
΢ÐÅ×Éѯ
¹Ø×¢¹«ÖÚºÅ
µ±Ç°Î»Öãº
